WOLF, Jonas Michel et al. Adverse drug events, comorbidities, and older age are statistically more prevalent in COVID-19 hospitalized patients treated with remdesivir than tocilizumab in a private hospital from southern Brazil. Clinical and Biomedical Research, [S. l.], v. 43, n. 3, 2023. DOI: 10.22491/2357-9730.129384. Disponível em: https://seer.ufrgs.br/index.php/hcpa/article/view/129384. Acesso em: 28 ago. 2026.